NYSE:ABBV - AbbVie Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$88.66 -0.84 (-0.94 %)
(As of 01/23/2019 06:05 AM ET)
Previous Close$89.50
Today's Range$87.90 - $89.36
52-Week Range$77.50 - $125.86
Volume5.66 million shs
Average Volume5.83 million shs
Market Capitalization$133.36 billion
P/E Ratio15.83
Dividend Yield4.78%
Beta1.46
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune diseases; IMBRUVICA, an oral therapy for treating chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C. It also provides Kaletra, an anti- human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid for hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, endometriosis, and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; and ZINBRYTA, a treatment for relapsing forms of multiple sclerosis. It serves wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has collaborations with Alector, Inc.; C2N Diagnostics; Voyager Therapeutics, Inc.; Janssen Biotech, Inc.; International Myeloma Foundation; Calibr and Scripps Research; The Institute for Research in Immunology and Cancer – Commercialization of Research; the Université de Montréal; Tolero Pharmaceuticals, Inc.; Galapagos; Mission Therapeutics Ltd; Bristol-Myers Squibb Company; and Voluntis. The company was incorporated in 2012 and is based in North Chicago, Illinois.

Receive ABBV News and Ratings via Email

Sign-up to receive the latest news and ratings for ABBV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP00287Y10
Phone847-932-7900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$28.22 billion
Cash Flow$6.5239 per share
Book Value$3.19 per share

Profitability

Net Income$5.31 billion

Miscellaneous

Employees29,000
Outstanding Shares1,504,220,000
Market Cap$133.36 billion
OptionableOptionable

AbbVie (NYSE:ABBV) Frequently Asked Questions

What is AbbVie's stock symbol?

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

How often does AbbVie pay dividends? What is the dividend yield for AbbVie?

AbbVie announced a quarterly dividend on Monday, November 5th. Investors of record on Tuesday, January 15th will be paid a dividend of $1.07 per share on Friday, February 15th. This represents a $4.28 annualized dividend and a dividend yield of 4.83%. The ex-dividend date is Monday, January 14th. This is a positive change from AbbVie's previous quarterly dividend of $0.96. View AbbVie's Dividend History.

How will AbbVie's stock buyback program work?

AbbVie declared that its board has authorized a stock repurchase program on Thursday, December 13th 2018, which permits the company to buyback $5,000,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to purchase up to 3.8% of its stock through open market purchases. Stock buyback programs are generally an indication that the company's leadership believes its stock is undervalued.

How were AbbVie's earnings last quarter?

AbbVie Inc (NYSE:ABBV) issued its quarterly earnings data on Friday, November, 2nd. The company reported $2.14 earnings per share for the quarter, topping the consensus estimate of $2.01 by $0.13. The business had revenue of $8.24 billion for the quarter, compared to analyst estimates of $8.23 billion. AbbVie had a return on equity of 2,006.63% and a net margin of 23.50%. The firm's revenue was up 17.7% compared to the same quarter last year. During the same period in the previous year, the business posted $1.41 earnings per share. View AbbVie's Earnings History.

When is AbbVie's next earnings date?

AbbVie is scheduled to release their next quarterly earnings announcement on Friday, January 25th 2019. View Earnings Estimates for AbbVie.

How can I listen to AbbVie's earnings call?

AbbVie will be holding an earnings conference call on Friday, January 25th at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link.

What guidance has AbbVie issued on next quarter's earnings?

AbbVie updated its FY18 earnings guidance on Friday, November, 2nd. The company provided earnings per share guidance of $7.90-7.92 for the period, compared to the Thomson Reuters consensus estimate of $7.88.

What price target have analysts set for ABBV?

18 brokerages have issued 12-month price targets for AbbVie's stock. Their predictions range from $65.61 to $144.00. On average, they anticipate AbbVie's share price to reach $100.0813 in the next twelve months. This suggests a possible upside of 12.9% from the stock's current price. View Analyst Price Targets for AbbVie.

What is the consensus analysts' recommendation for AbbVie?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 4 sell ratings, 7 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AbbVie.

What are Wall Street analysts saying about AbbVie stock?

Here are some recent quotes from research analysts about AbbVie stock:
  • 1. According to Zacks Investment Research, "AbbVie’s key drug, Humira has been performing well based on strong demand trends despite new competition. Moreover, Imbruvica has multibillion dollar potential. Mavyret’s launch has also been stronger than expected. AbbVie has also been successful in expanding approvals for its cancer drugs, Imbruvica and Venclexta. Moreover, AbbVie has an impressive late-stage pipeline comprising several products with multibillion-dollar potential expected to be launched in the near term. AbbVie expects to launch more than 20 new products or line extensions of marketed drugs before Humira biosimilar competition begins in the United States in 2023. AbbVie’s shares have outperformed the industry in the past one month. However, direct biosimilar competition to Humira in Europe from October can erode revenues in 2019. Nonetheless, estimates have gone up ahead of Q4 earnings. AbbVie has a positive record of earnings surprises in the recent quarters." (1/8/2019)
  • 2. BMO Capital Markets analysts commented, "On its fiscal 3Q18 earnings call, MDT said it does not expect the first-in- human use of its surgical robot in the next couple of months as the company had intended. Recall, MDT had previously said that it expected to be in clinical use by end of its fiscal 2018." (2/15/2018)

Has AbbVie been receiving favorable news coverage?

News stories about ABBV stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. AbbVie earned a media sentiment score of 1.0 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future.

Who are some of AbbVie's key competitors?

Who are AbbVie's key executives?

AbbVie's management team includes the folowing people:
  • Mr. Richard A. Gonzalez, Chairman & CEO (Age 65)
  • Mr. Carlos Alban, Vice Chairman & Chief Commercial Officer (Age 56)
  • Mr. Michael E. Severino, Vice Chairman & Pres (Age 53)
  • Mr. William J. Chase, Exec. VP of Fin. & Admin. (Age 51)
  • Ms. Laura J. Schumacher, Vice Chairman and External Affairs & Chief Legal Officer (Age 56)

Who are AbbVie's major shareholders?

AbbVie's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Retirement Systems of Alabama (0.08%), Ferguson Wellman Capital Management Inc. (0.05%), Gateway Investment Advisers LLC (0.05%), Hamlin Capital Management LLC (0.05%), Nisa Investment Advisors LLC (0.04%) and BB&T Corp (0.04%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Carlos Alban, Edward J Rapp, Glenn F Tilton, Henry O Gosebruch, Laura J Schumacher, Michael Severino, Richard A Gonzalez, Robert A Michael, Timothy J Richmond and William J Chase. View Institutional Ownership Trends for AbbVie.

Which major investors are selling AbbVie stock?

ABBV stock was sold by a variety of institutional investors in the last quarter, including First American Bank, KAMES CAPITAL plc, Gulf International Bank UK Ltd, Sit Investment Associates Inc., Bainco International Investors, Broadleaf Partners LLC, Chesley Taft & Associates LLC and BB&T Corp. Company insiders that have sold AbbVie company stock in the last year include Carlos Alban, Henry O Gosebruch, Laura J Schumacher, Michael Severino, Richard A Gonzalez, Robert A Michael, Timothy J Richmond and William J Chase. View Insider Buying and Selling for AbbVie.

Which major investors are buying AbbVie stock?

ABBV stock was purchased by a variety of institutional investors in the last quarter, including Retirement Systems of Alabama, Town & Country Bank & Trust CO dba First Bankers Trust CO, Weather Gauge Advisory LLC, Lavaca Capital LLC, Landsberg Bennett & Dubbaneh LLC, Beech Hill Advisors Inc., Nachman Norwood & Parrott Inc and Lynch & Associates IN. Company insiders that have bought AbbVie stock in the last two years include Edward J Rapp and Glenn F Tilton. View Insider Buying and Selling for AbbVie.

How do I buy shares of AbbVie?

Shares of ABBV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AbbVie's stock price today?

One share of ABBV stock can currently be purchased for approximately $88.66.

How big of a company is AbbVie?

AbbVie has a market capitalization of $133.36 billion and generates $28.22 billion in revenue each year. The company earns $5.31 billion in net income (profit) each year or $5.60 on an earnings per share basis. AbbVie employs 29,000 workers across the globe.

What is AbbVie's official website?

The official website for AbbVie is http://www.abbvie.com.

How can I contact AbbVie?

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company can be reached via phone at 847-932-7900.


MarketBeat Community Rating for AbbVie (NYSE ABBV)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  857 (Vote Outperform)
Underperform Votes:  528 (Vote Underperform)
Total Votes:  1,385
MarketBeat's community ratings are surveys of what our community members think about AbbVie and other stocks. Vote "Outperform" if you believe ABBV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABBV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel